Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $638000.0.

  • Inhibrx Biosciences' Amortization of Deferred Charges changed N/A to $638000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 4574.28%. This contributed to the annual value of $2.1 million for FY2024, which is 5784.85% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Amortization of Deferred Charges is $638000.0.
  • Inhibrx Biosciences' 5-year Amortization of Deferred Charges high stood at $1.2 million for Q4 2023, and its period low was $533000.0 during Q1 2025.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $823000.0 (2024), whereas its average is $906857.1.
  • The largest annual percentage gain for Inhibrx Biosciences' Amortization of Deferred Charges in the last 5 years was 2393.68% (2025), contrasted with its biggest fall of 5708.53% (2025).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Amortization of Deferred Charges stood at $1.2 million in 2023, then plummeted by 34.0% to $823000.0 in 2024, then fell by 22.48% to $638000.0 in 2025.
  • Its last three reported values are $638000.0 in Q3 2025, $626000.0 for Q2 2025, and $533000.0 during Q1 2025.